Candel Therapeutics Showcases Glioblastoma Immunotherapy Advances at Drug Development Summit

Reuters

02/11

Candel <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Showcases Glioblastoma Immunotherapy Advances at Drug Development <a href="https://laohu8.com/S/SMMT">Summit</a>

Candel Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies for cancer, will participate in the 7th Annual Glioblastoma Drug Development Summit from February 17-19, 2026, in Boston, Massachusetts. Dr. Francesca Barone, Candel's Chief Scientific Officer, will present data and insights from the company's HSV-based platform and the linoserpaturev (CAN-3110) program targeting recurrent high-grade glioma. Dr. Barone will be involved in several sessions, including a workshop panel on patient stratification using omics data (Feb. 17, 8:00 a.m. ET), a conference presentation on integrating biomarkers and imaging in a Phase I/II clinical trial (Feb. 18, 9:30 a.m. ET), and a panel discussion on biomarker-based enrollment in GBM trials (Feb. 18, 12:00 p.m. ET). Links to event-related documents and materials: - PDF Version

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief on February 11, 2026, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2610540930"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610540930\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610540930?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-11 21:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610540930","market":"nz","top_or_hot":-1,"title":"Candel Therapeutics Showcases Glioblastoma Immunotherapy Advances at Drug Development Summit","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Candel <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Showcases Glioblastoma Immunotherapy Advances at Drug Development <a href=\"https://laohu8.com/S/SMMT\">Summit</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Candel Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies for cancer, will participate in the 7th Annual Glioblastoma Drug Development Summit from February 17-19, 2026, in Boston, Massachusetts. Dr. Francesca Barone, Candel's Chief Scientific Officer, will present data and insights from the company's HSV-based platform and the linoserpaturev (CAN-3110) program targeting recurrent high-grade glioma. Dr. Barone will be involved in several sessions, including a workshop panel on patient stratification using omics data (Feb. 17, 8:00 a.m. ET), a conference presentation on integrating biomarkers and imaging in a Phase I/II clinical trial (Feb. 18, 9:30 a.m. ET), and a panel discussion on biomarker-based enrollment in GBM trials (Feb. 18, 12:00 p.m. ET). Links to event-related documents and materials: - PDF Version\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief on February 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Candel Therapeutics Showcases Glioblastoma Immunotherapy Advances at Drug Development Summit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCandel Therapeutics Showcases Glioblastoma Immunotherapy Advances at Drug Development Summit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-11 21:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Candel <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Showcases Glioblastoma Immunotherapy Advances at Drug Development <a href=\"https://laohu8.com/S/SMMT\">Summit</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Candel Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies for cancer, will participate in the 7th Annual Glioblastoma Drug Development Summit from February 17-19, 2026, in Boston, Massachusetts. Dr. Francesca Barone, Candel's Chief Scientific Officer, will present data and insights from the company's HSV-based platform and the linoserpaturev (CAN-3110) program targeting recurrent high-grade glioma. Dr. Barone will be involved in several sessions, including a workshop panel on patient stratification using omics data (Feb. 17, 8:00 a.m. ET), a conference presentation on integrating biomarkers and imaging in a Phase I/II clinical trial (Feb. 18, 9:30 a.m. ET), and a panel discussion on biomarker-based enrollment in GBM trials (Feb. 18, 12:00 p.m. ET). Links to event-related documents and materials: - PDF Version\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief on February 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDLc5ckyK:1","article_id":"2610540930","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610540930","pubTimestamp":1770815207,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Candel Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies for cancer, will participate in the 7th Annual Glioblastoma Drug Development Summit from February 17-19, 2026, in Boston, Massachusetts. Dr. Francesca Barone, Candel's Chief Scientific Officer, will present data and insights from the company's HSV-based platform and the linoserpaturev  program targeting recurrent high-grade glioma. Dr. Barone will be involved in several sessions, including a workshop panel on patient stratification using omics data , a conference presentation on integrating biomarkers and imaging in a Phase I/II clinical trial , and a panel discussion on biomarker-based enrollment in GBM trials . Links to event-related documents and materials: - PDF Version. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CADL":"Candel Therapeutics, Inc.","BK4539":"次新股"},"translate_title":"Candel Therapeutics在药物开发峰会上展示胶质母细胞瘤免疫疗法进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CADL":0.9},"content_text":"Candel Therapeutics Showcases Glioblastoma Immunotherapy Advances at Drug Development Summit\n\n\n        Candel Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies for cancer, will participate in the 7th Annual Glioblastoma Drug Development Summit from February 17-19, 2026, in Boston, Massachusetts. Dr. Francesca Barone, Candel's Chief Scientific Officer, will present data and insights from the company's HSV-based platform and the linoserpaturev (CAN-3110) program targeting recurrent high-grade glioma. Dr. Barone will be involved in several sessions, including a workshop panel on patient stratification using omics data (Feb. 17, 8:00 a.m. ET), a conference presentation on integrating biomarkers and imaging in a Phase I/II clinical trial (Feb. 18, 9:30 a.m. ET), and a panel discussion on biomarker-based enrollment in GBM trials (Feb. 18, 12:00 p.m. ET). Links to event-related documents and materials: - PDF Version\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Candel Therapeutics Inc. published the original content used to generate this news brief on February 11, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}